Loss of Y-Chromosome during Male Breast Carcinogenesis

被引：14

作者：

Agahozo, Marie Colombe ^{[1
]}

Timmermans, Mieke A. M. ^{[2
]}

Sleddens, Hein F. B. M. ^{[1
]}

Foekens, Renee ^{[2
]}

Trapman-Jansen, Anita M. A. C. ^{[2
]}

Schroder, Carolien P. ^{[3
]}

van Leeuwen-Stok, Elise ^{[4
]}

Martens, John W. M. ^{[2
]}

Dinjens, Winand N. M. ^{[1
]}

van Deurzen, Carolien H. M. ^{[1
]}

机构：

[1] Erasmus MC Canc Inst, Dept Pathol, NL-3015 GD Rotterdam, Netherlands

[2] Erasmus MC Canc Inst, Dept Med Oncol, NL-3015 GD Rotterdam, Netherlands

[3] Univ Med Ctr Groningen, Dept Med Oncol, NL-9700 AB Groningen, Netherlands

[4] BOOG Study Ctr, Dutch Breast Canc Res Grp, NL-1006 AE Amsterdam, Netherlands

来源：

CANCERS | 2020年 / 12卷 / 03期

关键词：

male breast cancer; loss of Y-chromosome; ductal carcinoma in situ; invasive breast cancer; progression; IN-SITU; CANCER; CARCINOMA; AGE;

D O I：

10.3390/cancers12030631

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Loss of Y-chromosome (LOY) is associated with increased cancer mortality in males. The prevalence of LOY in male breast cancer (BC) is unknown. The aim of this study is to assess the presence and prognostic effect of LOY during male BC progression. We included male BC patients diagnosed between 1989 and 2009 (n = 796). A tissue microarray (TMA) was constructed to perform immunohistochemistry and fluorescent in situ hybridization (FISH), using an X and Y probe. We also performed this FISH on a selected number of patients using whole tissue slides to study LOY during progression from ductal carcinoma in situ (DCIS) to invasive BC. In total, LOY was present in 12.7% (n = 92) of cases, whereby LOY was associated with ER and PR negative tumors (p = 0.017 and p = 0.01). LOY was not associated with the outcome. Using whole slides including invasive BC and adjacent DCIS (n = 22), we detected a concordant LOY status between both components in 17 patients. In conclusion, LOY is an early event in male breast carcinogenesis, which generally starts at the DCIS stage and is associated with ER and PR negative tumors.

引用

页数：11

共 24 条

[1] Male breast cancer: Looking for better prognostic subgroups [J].

Abreu, Miguel Henriques ;

Afonso, Noemia ;

Abreu, Pedro Henriques ;

Menezes, Francisco ;

Lopes, Paula ;

Henrique, Rui ;

Pereira, Deolinda ;

Lopes, Carlos .

BREAST, 2016, 26 :18-24

[2] Cytogenetic heterogeneity and clonal evolution in synchronous bilateral breast carcinomas and their lymph node metastases from a male patient without any detectable BRCA2 germline mutation [J].

Adeyinka, A ;

Mertens, F ;

Bondeson, L ;

Garne, JP ;

Borg, Å ;

Baldetorp, B ;

Pandis, N .

CANCER GENETICS AND CYTOGENETICS, 2000, 118 (01) :42-47

[3] Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program [J].

Cardoso, F. ;

Bartlett, J. M. S. ;

Slaets, L. ;

van Deurzen, C. H. M. ;

van Leeuwen-Stok, E. ;

Porter, P. ;

Linderholm, B. ;

Hedenfalk, I. ;

Schroder, C. ;

Martens, J. ;

Bayani, J. ;

van Asperen, C. ;

Murray, M. ;

Hudis, C. ;

Middleton, L. ;

Vermeij, J. ;

Punie, K. ;

Fraser, J. ;

Nowaczyk, M. ;

Rubio, I. T. ;

Aebi, S. ;

Kelly, C. ;

Ruddy, K. J. ;

Winer, E. ;

Nilsson, C. ;

Dal Lago, L. ;

Korde, L. ;

Benstead, K. ;

Bogler, O. ;

Goulioti, T. ;

Peric, A. ;

Litiere, S. ;

Aalders, K. C. ;

Poncet, C. ;

Tryfonidis, K. ;

Giordano, S. H. .

ANNALS OF ONCOLOGY, 2018, 29 (02) :405-417

[4] Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program [J].

Doebar, Shusma C. ;

Slaets, Leen ;

Cardoso, Fatima ;

Giordano, Sharon H. ;

Bartlett, John M. S. ;

Tryfonidis, Konstantinos ;

Dijkstra, Nizet H. ;

Schroder, Caroline P. ;

van Asperen, Christi J. ;

Linderholm, Barbro ;

Benstead, Kim ;

Dinjens, Winan N. M. ;

van Marion, Ronald ;

van Diest, Paul J. ;

Martens, John W. M. ;

van Deurzen, Carolien H. M. .

MODERN PATHOLOGY, 2017, 30 (04) :509-518

[5]

Federa.org, 2011, HUM TISS MED RES COD

[6] Male breast cancer is not congruent with the female disease [J].

Fentiman, Ian S. .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 101 :119-124

[7] Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer [J].

Forsberg, Lars A. ;

Rasi, Chiara ;

Malmqvist, Niklas ;

Davies, Hanna ;

Pasupulati, Saichand ;

Pakalapati, Geeta ;

Sandgren, Johanna ;

de Stahl, Teresita Diaz ;

Zaghlool, Ammar ;

Giedraitis, Vilmantas ;

Lannfelt, Lars ;

Score, Joannah ;

Cross, Nicholas C. P. ;

Absher, Devin ;

Janson, Eva Tiensuu ;

Lindgren, Cecilia M. ;

Morris, Andrew P. ;

Ingelsson, Erik ;

Lind, Lars ;

Dumanski, Jan P. .

NATURE GENETICS, 2014, 46 (06) :624-628

[8] Y-CHROMOSOME LOSS IN ESOPHAGEAL-CARCINOMA - AN IN-SITU HYBRIDIZATION STUDY [J].

HUNTER, S ;

GRAMLICH, T ;

ABBOTT, K ;

VARMA, V .

GENES CHROMOSOMES & CANCER, 1993, 8 (03) :172-177

[9] Male breast cancer, age and sex chromosome aneuploidy [J].

Jacobs, P. A. ;

Maloney, V. ;

Cooke, R. ;

Crolla, J. A. ;

Ashworth, A. ;

Swerdlow, A. J. .

BRITISH JOURNAL OF CANCER, 2013, 108 (04) :959-963

[10] Y chromosome loss is a frequent early event in urothelial bladder cancer [J].

Minner, Sarah ;

Kilgue, Adisa ;

Stahl, Phillip ;

Weikert, Steffen ;

Rink, Michael ;

Dahlem, Roland ;

Fisch, Margit ;

Hoeppner, Wolfgang ;

Wagner, Walter ;

Bokemeyer, Carsten ;

Terracciano, Luigi ;

Simon, Ronald ;

Sauter, Guido ;

Wilczak, Waldemar .

PATHOLOGY, 2010, 42 (04) :356-359

← 1 2 3 →